Is This a Sign That Biogen's Leqembi Could Obtain FDA Approval Next Month?
It was two years ago that 's (NASDAQ: BIIB) stock soared to more than $400 on news that its Alzheimer's treatment, Aduhelm (aducanumab), had obtained accelerated approval from the Food and Drug Administration (FDA).
Today, however, the company has given up on Aduhelm and is instead focusing on a potentially more promising Alzheimer's drug, Leqembi. It has already obtained accelerated approval and next month it could hit a much more important milestone: full, traditional approval.
Here's why it looks likely to happen and why that's so crucial for Biogen.
Source Fool.com
Biogen Inc. Aktie
185,65 €
1,50 %
Die Community zeigt großes Interesse an Biogen Inc. mit vielen Buy- und wenigen Sell-Einschätzungen.
Das Kursziel von 287 € für Biogen Inc. impliziert eine deutliche Steigerung um über 50% gegenüber 185.65 €.
